Gene Therapy Casgevy denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for gene therapy casgevy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Casgevy on Medical-Necessity Grounds

UnitedHealthcare's medical-necessity denials for Casgevy typically occur because the clinical submission did not satisfy each criterion in UHC's published coverage determination policy for this gene therapy. UHC's policies for high-cost gene therapies are detailed and require affirmative documentation of diagnosis, disease severity, prior treatment history, and treatment-center qualifications. A denial at this stage almost always means one or more documentation categories were missing, insufficiently detailed, or did not directly address the policy language.

## Why This Denial Is Appealable

Medical-necessity denials are the most commonly overturned category at external review. Under ACA §2719 and ERISA §503, an IRO applies clinical standards — not UHC's administrative preferences — and must find affirmative clinical support for the denial to uphold it. Patients who resubmit with complete, well-organized documentation that maps directly to each policy criterion have a meaningful chance of reversal.

## Federal Appeal Framework

• Internal appeal: File within the timeframe on the denial notice (typically 180 days). UHC must decide within 30 days (pre-service) or 60 days (post-service).
• Peer-to-peer review: Your hematologist can request a peer-to-peer call with UHC's medical director before or during the internal appeal — this is often the fastest path to reversal.
• External review: Request IRO review within approximately four months of the final internal denial. The IRO is independent of UHC.
• Expedited review: Available when standard timelines would seriously jeopardize health.

## Documentation to Gather

1. Diagnosis confirmation: Genetic testing results and laboratory records confirming sickle cell disease or transfusion-dependent beta-thalassemia. 2. Disease severity records: Comprehensive chart documentation — hospitalization dates, transfusion records, pain crisis frequency, organ-involvement assessments, and relevant imaging or specialist notes. 3. Prior treatment history: A chronological record of every prior disease-modifying therapy, including start dates, end dates, and documented clinical outcomes or reasons for discontinuation. 4. Treatment center qualification: Documentation that the administering center is an authorized Casgevy treatment site, as UHC typically requires care at a qualified facility. 5. Prescriber medical-necessity letter: A detailed letter from your hematologist that references the FDA-approved indication, the applicable ASH guidelines (generically), and addresses each UHC policy criterion individually.

## Criteria-Mapping Strategy

Download UHC's current coverage determination for Casgevy from UHC's provider portal or request it from member services. Build a table: each row is one policy criterion (copied verbatim); the corresponding cell identifies the specific document and chart entry that satisfies it. Attach all supporting documents as labeled exhibits. An appeal that is organized this way removes the reviewer's ability to find an unaddressed requirement and is the single most effective format for a medical-necessity reversal.